Cantex's pipeline has two product candidates in clinical development for diseases where innovative and more effective treatments are greatly needed. DSTAT (formerly known as CX-01) for the treatment of acute lung injury (ALI) in COVID-19 patients and acute myeloid leukemia (AML). Dicopp® for the treatment of metastatic pancreatic cancer, recurrent/refractory multiple myeloma, and recurrent pediatric sarcoma.
page-template,page-template-full_width,page-template-full_width-php,page,page-id-16915,bridge-core-1.0.6,ajax_fade,page_not_loaded,,qode_grid_1200,qode-theme-ver-18.2,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.4.1,vc_responsive


Cantex has three product candidates in clinical development:



  • Azeliragon, an oral, small molecule, Phase 2-ready compound, administered once-daily, that inhibits RAGE interactions with its natural ligands, including HMGB1 and S100 proteins produced by cancer cells
  • Although azeliragon did not show efficacy in a Phase 3 trial in Alzheimer’s disease, clinical safety data, with over 1200 individuals dosed, indicates high level of safety and tolerability
  • There has been extensive demonstration of Azeliragon’s pre-clinical efficacy in animal models of diverse serious complications of cancer, including cachexia, cancer bone pain, and lung metastasis–common, disabling and potentially life-threatening cancer complications driven by RAGE axis signaling
  • Cantex is planning Phase 2 trials in pancreatic cancer and breast cancer



  • Blocks mechanisms essential for cancer cell survival
  • Phase 2 trials in 2021 and 2022
    • Relapsed/refractory myeloma: Phase 1/2 in progress
    • Relapsed/refractory myelodysplastic syndrome: planned
  • Cantex owns issued and pending intellectual property for Dicopp®
  • Dicopp® is a 505(b)(2)product



  • Licensed to Chimerix in July 2019. Continued participation in development via Joint Development Committee.
    • Key deal terms
      • $30 million upfront
      • 10 million shares of Chimerix (NASDAQ:CMRX) common stock. We retain these 10 million shares.
      • Payments for achieving sales milestones and regulatory approvals totaling $587.5 million
      • Tiered double-digit royalties on net sales
  • Completed randomized Phase 2 study in acute myeloid leukemia (AML) suggested DSTAT + “7+3” improves event-free and relapse-free survival as well as overall survival without additive toxicity
  • Phase 3 clinical trial in AML is in progress.
Cantex pipeline graphic